Evaluation of locoregional recurrence in patients with early breast carcinoma post-breast-conserving surgery with and without the use of preoperative chemotherapy

Samer Makki Mohamed Al-Hakkak¹, Saad Ab-razq Mijbas², Noor Abdulmunem salman Al-Bdiri³, Hassan Abdulla Abadi AL-Aquli²

¹Department of Surgery, Faculty of Medicine, Jabir Ibn Hayyan Medical University, Najaf city, Iraq
²Department of Surgery, College of Medicine, Kufa University, Najaf city, Iraq
³Department of surgery, AL sadder Medical City, Ministry of Health, Najaf City, Iraq

Article History:
Received on: 16.Jan.2020
Revised on: 10.Feb.2020
Accepted on: 14.Feb.2020

Keywords:
Breast conserving surgery, adjuvant chemotherapy, local recurrence, Breast carcinoma, neoadjuvant chemotherapy

ABSTRACT

The effects of neoadjuvant chemotherapy in increasing the rate of conserva-tive breast therapy and associated with reducing morbidity and better cosmetic has been fully acknowledged. Now, there are commonly used neoadjuvant chemotherapy for operable early breast carcinomas patients. Currently, neoadjuvant chemotherapy is used for locally advanced breast carcinoma, inflammatory breast cancer, and down staging of the large tumour to allow for breast conservativetherapy. A prospective study performed in the department of surgery in Al-Sadder Medical City/Najaf city/Iraq, from the month of October 2015 to the 1st of October 2018, where 48 patients presented with a breast cancer diagnosis by clinical examination, Mammography, breast ultrasound, chest x-ray, bone scan, serum CEA, CA15_3 level, the initial diagnosis of breast cancer made by core needle biopsy. Breast saving surgery consisted of wide local excision with a safe margin with standard level I, II lymph node of axilla dissection. The resected specimen and lymph node was sent for histopathological examination; the size, width, length & height dimension were recorded and the resection margin was recorded positive if close to 2mm and negative if >2mm tumortumor-free margin. The A 48 patients enrolled in this study with a mean age at diagnosis of 44.6 ± 8.4 years. 34 patients received neoadjuvant chemotherapy. Locoregional recurrence reported in 4 patients (28.6%) not received neoadjuvant chemotherapy (P.value< 0.001), the higher relapse rate was reported significantly in the cases aged more than 50 years compared to those aged 50 years or below (P. value = 0.05, significant). Neoadjuvant chemotherapy decreases the incidence of locoregional recurrence of early breast carcinoma after breast-conserving surgery.

INTRODUCTION

Neoadjuvant chemotherapy (NAC) is the giving of systemic treatment before the excision of a tumor surgically. NAC primary was fashioned to be utilized in locally advanced patients to transform non-operable tumors into operable one. As this idea of preface, the significance of NAC in raising the preservation surgery rate with decreased morbidity and better cosmetics. Meantime, there have been interesting about to control the tumor locally
over the down-staging of the neoplasm and the postponement of surgery, inpatient resistant to NAC (Kuerer et al., 1999; Smith and Lipton, 2001). Yet, the study on a randomized trial comparing the competence of NAC with adjuvant chemotherapy in operable patients with breast carcinoma has shown equal results. The study was set up on 5500 desirable women for these analyses. It also stated that NAC prevents mastectomy in twenty-five percent of the patients. In contrast, less than five percent of the patients who were a primary nominee for preservation treatment need an excision of the breast because of disease progression whilst taking NAC (Mieog et al., 2007a; Kaufmann et al., 2003). NAC at present is usually used for early operable patients with breast carcinoma. Currently, NAC is utilized for locally advanced carcinoma of the breast, inflammatory breast cancer; and down-staging of big tumors to permit for breast preservation treatment (Rouzier, 2005; Mauri et al., 2005). The usage for NAC at present expanded to clinically node-negative breast cancer patients with inappropriate/unappropriated tumor profiles, in whom adjuvant systemic treatment is foretell (Vugts et al., 2016; Shin et al., 2013). Various benefits of the utility of NAC. It shows a single chance for the assessment of management responds with full pathologic response doing as a replacement marker of existence and for more prompt evaluation of the effectiveness of new therapeutic factors and early stopping of inefficient therapy. Also, in case of reluctance to therapy, adjusting the dose and/or alteration of other drug conserve patients from a load of side effects and toxicity. Moreover, NAC tailored to each individualized patient (Sahoo et al., 2012; Fisher et al., 2002). Response to NAC can be evaluated by clinical checking, breast imaging investigations, and, lastly, pathologic examination of post-treatment specimens. A clinical checkup is done by evaluation of the size of the tumor by palpation. This job is harder in tumors that have reacted to treatment, as it is defying to palpate the real tumor against the therapy-induced changes (Pierga et al., 2003; Mieog et al., 2007b). The breast imaging form such as ultrasound and mammography are not deemed sufficient for quantitative evaluation of variation in size of the tumor imaging. However, more modern apparatus such as MRI (magnetic resonance imaging) and PET (positron emission tomography) have been shown to supply a better evaluation of tumor reply to NAC and better portend reply to treatment (Keune et al., 2010; Partridge et al., 2005). The gross examination was the gateway to the input the location and the size and of the neoplasm before the treatment is critical. Sample radiography will help with the identity of clips or micro-calcifications. Correlated with entire responded to treatments, it is impossible to recognize any grossly visible lesions. The identity of the neoplasm mattress and surrounding tissue helps select the right tissue sectioning area. So, pains should be made to assess the surgical margins since the tumor mattress are usually seen as a non-descriptive area of irregular rubbery fibrous tissue that may also contain ill-defined areas of residual tumor. The tumor size mattress should also be documented. The important margin assessment in case the residual neoplasm is later found by microscopic examination. (Sahoo and Lester, 2009; Liu et al., 2010). The microscopic evaluation, it is remarkable microscopically to detect the prior biopsy alterations recognized by stromal fibrosis, macrophage, lymphocytes, and, sometimes, a multinucleated giant cell response. In the lack of this feedback, the tolerance of specimen mistakes in the lumpectomy sample should be so deemed. Likely, understanding of the tumor mattress is fundamental. Neoplasm mattress are distinguished by chronic inflammatory penetrate, necrosis, stromal fibrosis, calcifications, and histiocytic (Londero et al., 2004; Sahoo et al., 2012). The series of alterations after treatments is known as full respond “no residual tumor identified”; partial response (residual tumor is seen singly or in the cluster), and non-response “no change identified; at some times, it is rough to set between reactive/inflammatory atypia and residual neoplastic cells”. Alterations in non-tumor tissue of the breast contain nuclear enlargement, cytoplasmic and basement membranes sclerosis may similar to a residual neoplasm. In such a situation, immunostaining for epithelial markers such as cytokeratin-1/AE3 or CK7 and CD68 for histiocytic and myoepithelial markers are suitable diagnostic assistants (Chen et al., 2008; Sahoo and Lester, 2009). The perfect pathologic restrain includes the disappearance of all axillary lymph nodes and invasive carcinoma in the breast after the accomplishment of treatments.

PATIENT AND METHODS

A prospective study performed in the department of surgery in Al-Sadder Mmedical City, Najaf city, from October 1, 2015, to October 1, 2018, where 48 patients presented breast cancer with the clinical checkup. Mammmography, breast ultrasound, CXR, bone scan, serum CEA CA15_3 level, the initial breast cancer diagnosis made by core needle biopsy. All enrolled patients were undergoing breast-conserving surgery(BCS) with lymph node axillary dissection followed by radiotherapy with systemic adjuvant therapy, but not all patients with
Table 1: Age distribution of studied group

| Size | Neo adjuvant chemotherapy | Non-Neo Adjuvant chemotherapy |
|------|----------------------------|-----------------------------|
| T1   | No. 4                       | No. 4                       |
|      | % 11.8%                     | % 28.6%                     |
| T2   | No. 30                      | No. 10                      |
|      | % 88.2%                     | % 71.4%                     |
| Total| No. 34                      | No. 14                      |
|      | % 100%                      | % 100%                      |

P.value = 0.322 (not significant)

Table 2: Descriptive statistics of lymph nodes status in patient received Neoadjuvant chemotherapy or not

| LN   | Neo adjuvant chemotherapy | Non-Neo adjuvant chemotherapy |
|------|----------------------------|-----------------------------|
| N0   | No. 18                     | No. 4                       |
|      | % 52.9%                    | % 28.6%                     |
| N1   | No. 16                     | No. 10                      |
|      | % 47.1%                    | % 71.4%                     |
| Total| No. 34                     | No. 14                      |
|      | % 100%                     | % 100%                      |

P.value = 0.221 (not significant)

Table 3: Descriptive Statistics of hormones status in patients received Neoadjuvant chemotherapy or not

| Hormones receptors | Neo adjuvant chemotherapy | Non-Neo adjuvant chemotherapy |
|--------------------|----------------------------|-----------------------------|
| ER+ve, PR+ve, HER2+ve | No. 8                     | No. 6                       |
|                    | % 23.5%                    | % 42.9%                     |
| ER+ve, PR+ve, HER2-ve | No. 22                    | No. 8                       |
|                    | % 64.7%                    | % 57.1%                     |
| Triple-ve          | No. 4                      | No. 0                       |
|                    | % 11.8%                    | % 0                         |
| Total              | No. 34                     | No. 14                      |
|                    | % 100%                     | % 100%                      |

P.value = 0.222 (not significant)

Table 4: Distribution of Locoregional recurrence among the studied group

| Locoregional recurrence | Neo adjuvant chemotherapy | Non-Neo adjuvant chemotherapy |
|------------------------|----------------------------|-----------------------------|
| No                     | No. 34                     | No. 10                      |
|                        | % 100%                     | % 71.4%                     |
| Yes                    | No. 0                      | No. 4                       |
|                        | % 0                        | % 28.6%                     |
| Total                  | No. 34                     | No. 14                      |
|                        | % 100%                     | % 100%                      |

P.value <0.001 (significant)

Table 5: Relationship Locoregional recurrence regarding age

| Age (Year) | Yes (n=6) | No (n=42) |
|------------|------------|------------|
|            | Relapse    |            |
|            | No         | Yes        |
| = 50       | 39         | 2.5        |
| > 50       | 3          | 37.5       |

Fisher’s Exact test = 9.44, P.value 0.0119 (significant)
Table 6: Descriptive Statistics of grade in patients received Neo adjuvant chemotherapy or not

| Grade |Neo adjuvant chemotherapy| Non-Neo adjuvant chemotherapy|
|-------|--------------------------|-----------------------------|
|       | No. | %     | No. | %     |
| I     | 8   | 23.5 %| 2   | 14.3 %|
| II    | 24  | 70.6 %| 10  | 71.4 %|
| III   | 2   | 5.9 % | 2   | 14.3 %|
| Total | 34  | 100 % | 14  | 100 % |

P.value = 0.535 (not significant)

Table 7: Results of Binary Regression analysis

| Variable in the equation | Odd ratio | P.value |
|--------------------------|-----------|---------|
| Age at diagnosis (older than 50) | 1.05 | 0.06 |
| Tumor size (>=5 cm) | 1.09 | 0.043 |
| TNM staging (advanced) | 0.63 | <0.001 |
| Grade (advanced) | 0.59 | <0.001 |
| Adjuvant Radiotherapy (Yes) | 1.00 | 0.38 |
| Adjuvant chemotherapy (Yes) | 0.96 | 0.42 |
| Hormonal Therapy (Yes) | 1.00 | 0.95 |

Follow up

The patient was followed by a 6-month interval for 3 years; the patients were evaluated by clinical examination and radiological evaluation and if any suspicions of recurrent confirm by core needle biopsy. Locoregional recurrence was defined by ipsilateral breast axillary, internal mammary supraclavicular and infraclavicular lymph node.

Statistical analysis

Data were entered and resolved using the statisti-
pecial package for social sciences (SPSS) version 25. Descriptive statistics presented as standard deviation, mean, frequencies, and percentages. We used a chi-square test to evaluate the relevance between categorical variables, Fisher’s exact test used when chi-square was inapplicable. Binary regression analysis used to assess the relevance between relapse and other variables with adjustment for confounders. The level of significance of ≤ 0.05 was deemed significant.

RESULTS AND DISCUSSION

48 patients had registered in this study with a mean age at diagnosis of 44.6 ± 8.4 (Range: 31 – 66) years, moreover, 37 patients (77.1%) aged below 50 years, (Figure 1). The total patients registered in this research were divided into 34 patients who received NAC, 4 patients (11.8%) tumor size were T1 and 30 patients (88.2%) tumor size were T2, other 14 patients had not received NAC 4 patients (28.6%) tumor size were T1 and 10 patients (71.4%) tumor size were T2 the P. Value = 0.322 (not significant), (Table 1). With regard to lymph node status, 18 patients (52.9%) lymph node status were N0 and 16 patients (47.1%) lymph node status were N1 in the NAC group, while 4 patients (28.6%) lymph node status were N0 and 10 patients (47.1%) lymph node status was N1 in the non-NAC group with P. Value = 0.322 (not significant), (Table 2). For the hormonal status of the studied group, each of ER-positive, PR positive and HER2 positive reported in 8 (23.5%) in patients received NAC while 6 patients (42.9%) in patients did not receive NAC, each of ER-positive, PR positive and HER2 negative reported in 22 (64.7%) in patients received NAC while 8 patients (57.1%), where triple negative 4 (11.8%) in patients received NAC and 0 (0.0%) in patients did not receive NAC (Table 3). Locoregional recurrence reported in 4 patients (28.6%) did not receive NAC P. Value < 0.001 (significant) As in (Table 4), higher relapse rate was reported significantly in the cases aged more than 50 years compared to those aged 50 years or below, 37.5% vs. 7.5%, respectively, (P. Value = 0.05, significant) (Table 5enrolled). More analysis was done early in the relationship between locoregional recurrence and grade, where statistically not significant results of this analysis are seen in (Table 6). Further assessment was done for the correlation between locoregional recurrence and other variables in addition to mode of treatment using the bivariate regression analysis, which was used to control any confounding effect and inter-correlation between these variables which may affect the significance of correlation between relapse and adjuvant therapy, however, the correlation still insignificant after modulation for other significant variables; age, tumor size, TNM staging, and grades, P>0.05) (Table 7).

Locoregional recurrence (LRR) after BCS is a well-known independent risk factor associated with unfavorable long-period results. Debate occurs regarding the predicted effect of an LRR post long incident-free period (van Laar et al., 2013; Gosset et al., 2016). Our research tries to assess the benefit of neoadjuvant treatment before surgery on the recurrence of breast cancer among a group of Iraqi patients, therefore an overall of 48 patients registered in our research. The majority of the patients in the studied group aged 50 years or more, which indicated the higher breast cancer incidence among this age group, which is similar to previous epidemiological studies regarding the distribution of age of patients with breast carcinoma. (Rottenberg et al., 2018; Agarwal et al., 2018). The present study found a higher recurrence rate among patients aged 50 years or older, compared to younger age groups, 37.5% Vs. 7.5%, respectively, Conversely, Shin et al. From the Republic of Korea, reported in 2018 that the younger age ≤ 40 years were associated with worse recurrence. (Sweeting et al., 2011; Shin et al., 2018). It is recognized that NAC can effectively downstage the main neoplasm. For patients with huge neoplasms permitting breast excision at the first diagnosis, the utilize of NAC has been seen to decrease the size of the main neoplasm and make a possible breast conserving surgery (Kuerer et al., 2001; Vlastos et al., 2000). The NSABP-B18 trial demonstrated higher locoregional recurrence following surgery in the -NAC BCS group parallel with the NAC –breast excision group (Wolmark et al., 2001). Three studies backed the idea that BCS after in NAC patients with big initial breast neoplasm could be a logical therapy choice if the tumor size decreased to ≤ 4 cm after NAC regardless of the primary size of the tumor. But, patients who exhibit no restraint to NAC submitting BCS had a significantly higher local relapse rate contrast to breast excision patients. But, because of significant variation in the state of the lymph nodes, grading, and size of the tumor between the two groups, the outcome has to be seen with caution (Parmar et al., 2006; Shin et al., 2013). Several studies explained that BCS after NAC is a logical choice for female who respond to NAC. But, our research has various restrictions. First of all, it was a retrospective research, and that may become favorable in the data analyzed. Secondly, the local recurrence rate was weak and the follow-up of some researches (Parmar et al., 2006; Cho et al., 2013) were so short. This may have been a cause of why these researches...
drop to detect a variation in local recurrence rates among groups. More studies and researches must be done with proper recording of recurrence established on stage and 10-year follow-up post-surgery, which would then permit the doctors to better counsel patients about breast-conserving surgery-NAC for locoregional recurrence post BCS.

CONCLUSIONS

Utilization of neoadjuvant chemotherapy in this research was accompanied with neoplasm plus axillary down staging, which increased the number of cases undergoing breast conservation, so Neo adjuvant chemotherapy reduces the incidence of locoregional recurrence of early breast carcinoma after breast conserving surgery. Many multi-centre researches studies with a prolonged follow-up are required to compare the total and disease-free survival advantage of this management modality.

Ethical approval
The ethical committee of the, Faculty of Medicine, Jabir Ibn Hayyan Medical University

Funding
No funding

Conflict of interest statement
All authors stat they don’t have any conflict of interest.

Declarations
Ethical consent has been taken from all patients.

REFERENCES

Agarwal, G., Sonthineni, C., Mayilvaganan, S., Mishra, A., Lal, P., Agrawal, V. 2018. Surgical Outcomes of Primary Versus Post-Neoadjuvant Chemotherapy Breast Conservation Surgery: A Comparative Study from a Developing Country. World Journal of Surgery, 42(5):1364–1374.

Chen, J. H., Feig, B., Agrawal, G., Yu, H., Carpenter, P. M., Mehta, R. S., Nalcioglu, O., Su, M. Y. 2008. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer, 112(1):17–26.

Cho, J. H., Park, J. M., Park, H. S., Park, S., Kim, S., II, Park, B. W. 2013. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Surgical Oncology, 108(8):531–536.

Fisher, E. R., Wang, J., Bryant, J., Fisher, B., Mamounas, E., Wolmark, N. 2002. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer, 95(4):681–695.

Gosset, M., Hamy, A.-S., Mallon, P., Delomenie, M., Mouttet, D., Pierga, J.-Y., Lae, M., Fourquet, A., Rouzier, R., Reyal, F., Feron, J.-G. 2016. Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. PLOS ONE, 11(8):e0159888–e0159888.

Kaufmann, M., von Minckwitz, G., Smith, R., Valero, V., Gianni, L., Eiermann, W., Howell, A., Costa, S. D., Beuzeboc, P., Untch, M., Blohmer, J.-U., Sinn, H.-P., Sittek, R., Souchon, R., Tulusan, A. H., Volm, T., Senn, H.-J. 2003. International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations. Journal of Clinical Oncology, 21(13):2600–2608.

Keune, J. D., Jeffe, D. B., Schootman, M., Hoffman, A., Gillanders, W. E., Aft, R. L. 2010. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. The American Journal of Surgery, 199(4):477–484.

Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Singletary, S. E. 1999. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 17(2):460–469.

Kuerer, H. M., Singletary, S. E., Buzdar, A. U., Ames, F. C., Valero, V., Buchholz, T. A., Ross, M. I., Pusztai, L., Hortobagyi, G. N., Hunt, K. K. 2001. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. The American Journal of Surgery, 182(6):601–608.

Liu, S. V., Melstrom, L., Yao, K., Russell, C. A., Sener, S. F. 2010. Neoadjuvant therapy for breast cancer. Journal of Surgical Oncology, 101(4):283–291.

Londero, V., Bazzocchi, M., Frate, C. D., Pugliisi, F., Loreto, C. D., Francescutti, G., Zuiani, C. 2004. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. European Radiology, 14(8):1371–1379.

Mauri, D., Pavlidis, N., Ioannidis, J. P. A. 2005. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. JNCI Journal of the National Cancer Institute, 97(3):188–194.

Mieog, J. S. D., Hage, J. A. V. D., Velde, C. J. H. V. D. 2007a. Preoperative chemotherapy for
women with operable breast cancer. The Cochrane Database of Systematic Reviews, pages 5002–05002.

Mieog, J. S. D., van der Hage, J. A., van de Velde, C. J. H. 2007b. Neoadjuvant chemotherapy for operable breast cancer. British Journal of Surgery, 94(10):1189–1200.

Parmar, V., Krishnamurthy, A., Hawaldar, R., Nadkarni, M. S., Sarin, R., Chinoy, R., Nair, R., Dinshaw, K. A., Badwe, R. A. 2006. Breast conservation treatment in women with locally advanced breast cancer – Experience from a single centre. International Journal of Surgery, 4(2):106–114.

Partridge, S. C., Gibbs, J. E., Lu, Y., Esserman, L. J., Tripathy, D., Wolverton, D. S., Rugo, H. S., Hwang, E. S., Ewing, C. A., Hylton, N. M. 2005. MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival. American Journal of Roentgenology, 184(6):1774–1781.

Pierga, J. Y., Mouret, E., Laurence, V., Diéras, V., Savigioni, A., Beuzeboc, P., Dorval, T., Palangié, T., Jouve, M., Pouillart, P. 2003. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. European Journal of Cancer, 39(8):1089–1096.

Rottenberg, Y., Naeim, A., Uziely, B., Peretz, T., Jacobs, J. M. 2018. Breast cancer among older women: The influence of age and cancer stage on survival. Archives of Gerontology and Geriatrics, 76:60–64.

Rouzier, R. 2005. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research, 11(16):5678–5685.

Sahoo, S., Dabbs, D. J., Bhargava, R. 2012. Pathology of neoadjuvant response of breast carcinoma. Breast pathology, 1:519–535.

Sahoo, S., Lester, S. C. 2009. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Archives of Pathology & Laboratory Medicine, 133(4):633–642.

Shin, H. C., Han, W., Moon, H. G., Im, S. A., Moon, W. K., Park, I. A., Noh, D. Y. 2013. Breast-Conserving Surgery After Tumor Downstaging by Neoadjuvant Chemotherapy is Oncologically Safe for Stage III Breast Cancer Patients. Annals of Surgical Oncology, 20(8):2582–2589.

Shin, S. U., Cho, N., Lee, H. B., Kim, S. Y., Yi, A., Kim, S. Y., Moon, W. K. 2018. Neoadjuvant Chemotherapy and Surgery for Breast Cancer: Preoperative MRI Features Associated with Local Recurrence. Radiology, 289(1):30–38.